PARIS (Reuters) - For pharmaceutical companies, Africa is changing. Not only is the continent's economic growth grabbing attention in boardrooms but the shifting nature of its disease burden is luring Big Pharma, as new opportunities open up for treating chronic diseases afflicting the middle classes, rather than just fire-fighting infection. European companies, in particular, hope to reap rewards by investing early in a region where many of them already have historic commercial ties. ...
Get the complete story
No comments:
Post a Comment